Crizotinib in the treatment of non--small-cell lung cancer.
作者： Sacha I. Rothschild , Oliver Gautschi
DOI: 10.1016/J.CLLC.2013.04.006
关键词:
摘要: An anaplastic lymphoma kinase (ALK) translocation giving rise to activated ALK tyrosine is present in approximately 5% of non-small-cell lung cancers (NSCLCs). Crizotinib an oral inhibitor targeting ALK, met proto-oncogene, and c-ros oncogene 1 (ROS1). It was recently approved several countries for the treatment patients with advanced, ALK-rearranged NSCLC. In 2012, results from first phase III trial showing superiority crizotinib compared standard chemotherapy second-line ALK-positive NSCLC were presented. Furthermore, shown be active ROS1-rearranged Here, we give overview molecular pathogenesis NSCLC, pharmacokinetic pharmacodynamic properties crizotinib, clinical trials
elsevier.com
sci-hub.se 参考文章(95)
Giorgio Scagliotti, Nasser Hanna, Frank Fossella, Katherine Sugarman, Johannes Blatter, Patrick Peterson, Lorinda Simms, Frances A. Shepherd, The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies Oncologist. ,vol. 14, pp. 253- 263 ,(2009) , 10.1634/THEONCOLOGIST.2008-0232
Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher Lathan, J. Paul Marcoux, Jinyan Du, Katsuhiro Okuda, Marzia Capelletti, Takeshi Shimamura, Dalia Ercan, Magda Stumpfova, Yun Xiao, Stanislawa Weremowicz, Mohit Butaney, Stephanie Heon, Keith Wilner, James G. Christensen, Michel J. Eck, Kwok-Kin Wong, Neal Lindeman, Nathanael S. Gray, Scott J. Rodig, Pasi A. Jänne, A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors Cancer Research. ,vol. 71, pp. 6051- 6060 ,(2011) , 10.1158/0008-5472.CAN-11-1340
Daniel B. Costa, Susumu Kobayashi, Shuchi S. Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D. Wilner, CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib Journal of Clinical Oncology. ,vol. 29, ,(2011) , 10.1200/JCO.2010.34.1313
J. G. Christensen, H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, S. Yamazaki, G. R. Alton, B. Mroczkowski, G. Los, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Molecular Cancer Therapeutics. ,vol. 6, pp. 3314- 3322 ,(2007) , 10.1158/1535-7163.MCT-07-0365
Scott J Rodig, Mari Mino-Kenudson, Sanja Dacic, Beow Y Yeap, Alice Shaw, Justine A Barletta, Hannah Stubbs, Kenny Law, Neal Lindeman, Eugene Mark, Pasi A Janne, Thomas Lynch, Bruce E Johnson, A John Iafrate, Lucian R Chirieac, None, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clinical Cancer Research. ,vol. 15, pp. 5216- 5223 ,(2009) , 10.1158/1078-0432.CCR-09-0802
Ji-Youn Han, Keunchil Park, Sang-We Kim, Dae Ho Lee, Hyae Young Kim, Heung Tae Kim, Myung Ju Ahn, Tak Yun, Jin Seok Ahn, Cheolwon Suh, Jung-Shin Lee, Sung Jin Yoon, Jong Hee Han, Jae Won Lee, Sook Jung Jo, Jin Soo Lee, First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung Journal of Clinical Oncology. ,vol. 30, pp. 1122- 1128 ,(2012) , 10.1200/JCO.2011.36.8456
Hyojin Kim, Seol-Bong Yoo, Ji-Young Choe, Jin Ho Paik, Xianhua Xu, Hiroaki Nitta, Wenjun Zhang, Thomas M. Grogan, Choon-Taek Lee, Sanghoon Jheon, Jin-Haeng Chung, Detection of ALK gene rearrangement in non-small cell lung cancer: A comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression Journal of Thoracic Oncology. ,vol. 6, pp. 1359- 1366 ,(2011) , 10.1097/JTO.0B013E31821CFC73
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, Li Zhang, Changxuan You, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncology. ,vol. 12, pp. 735- 742 ,(2011) , 10.1016/S1470-2045(11)70184-X
Beow Y Yeap, Benjamin J Solomon, Gregory J Riely, Justin Gainor, Jeffrey A Engelman, Geoffrey I Shapiro, Daniel B Costa, Sai-Hong I Ou, Mohit Butaney, Ravi Salgia, Robert G Maki, Marileila Varella-Garcia, Robert C Doebele, Yung-Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D Wilner, Eunice L Kwak, Jeffrey W Clark, A John Iafrate, D Ross Camidge, Alice T Shaw, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncology. ,vol. 12, pp. 1004- 1012 ,(2011) , 10.1016/S1470-2045(11)70232-7
J Guillermo Paez, Pasi A Janne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J Eck, William R Sellers, Bruce E Johnson, Matthew Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. ,vol. 304, pp. 1497- 1500 ,(2004) , 10.1126/SCIENCE.1099314